Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Strong

Showing results (311-320 of 338) with videos related to

Pageof 34
Sort By:
BMC Cancer|October 6, 2011
Activating mutation in MET oncogene in familial colorectal cancerDeborah W Neklason, Michelle W Done, Nykole R Sargent, et al.
Genome Research|August 21, 2020
A pedigree-based prediction model identifies carriers of deleterious de novo mutations in families with Li-Fraumeni syndromeFan Gao, Xuedong Pan, Elissa B Dodd-Eaton, et al.
Cancer Research|November 14, 2019
Penetrance of Different Cancer Types in Families with Li-Fraumeni Syndrome: A Validation Study Using Multicenter CohortsSeung Jun Shin, Elissa B Dodd-Eaton, Gang Peng, et al.
Plos One|March 13, 2015
Characterization of genomic alterations in radiation-associated breast cancer among childhood cancer survivors, using comparative genomic hybridization (CGH) arraysXiaohong R Yang, J Keith Killian, Sue Hammond, et al.
The New England Journal of Medicine|March 15, 2013
Increased oxidative metabolism in the Li-Fraumeni syndromePing-Yuan Wang, Wenzhe Ma, Joon-Young Park, et al.
Geroscience|October 23, 2023
Inhibition of p53-MDM2 binding reduces senescent cell abundance and improves the adaptive responses of skeletal muscle from aged miceGeorgia L Nolt, Alexander R Keeble, Yuan Wen, et al.
Nature Medicine|July 26, 2011
Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphomaTimothy Best, Dalin Li, Andrew D Skol, et al.
Breast Cancer Research and Treatment|April 4, 2014
Long-term risk of medical conditions associated with breast cancer treatmentDeirdre A Hill, Nora K Horick, Claudine Isaacs, et al.
JAMA|July 14, 2011
Clinically relevant changes in family history of cancer over timeArgyrios Ziogas, Nora K Horick, Anita Y Kinney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2006
Characterization of BRCA1 and BRCA2 mutations in a large United States sampleSining Chen, Edwin S Iversen, Tara Friebel, et al.
Pageof 34

Showing results (311-320 of 338) with videos related to

Sort By:
Pageof 34
BMC Cancer|October 6, 2011
Activating mutation in MET oncogene in familial colorectal cancerDeborah W Neklason, Michelle W Done, Nykole R Sargent, et al.
Genome Research|August 21, 2020
A pedigree-based prediction model identifies carriers of deleterious de novo mutations in families with Li-Fraumeni syndromeFan Gao, Xuedong Pan, Elissa B Dodd-Eaton, et al.
Cancer Research|November 14, 2019
Penetrance of Different Cancer Types in Families with Li-Fraumeni Syndrome: A Validation Study Using Multicenter CohortsSeung Jun Shin, Elissa B Dodd-Eaton, Gang Peng, et al.
Plos One|March 13, 2015
Characterization of genomic alterations in radiation-associated breast cancer among childhood cancer survivors, using comparative genomic hybridization (CGH) arraysXiaohong R Yang, J Keith Killian, Sue Hammond, et al.
The New England Journal of Medicine|March 15, 2013
Increased oxidative metabolism in the Li-Fraumeni syndromePing-Yuan Wang, Wenzhe Ma, Joon-Young Park, et al.
Geroscience|October 23, 2023
Inhibition of p53-MDM2 binding reduces senescent cell abundance and improves the adaptive responses of skeletal muscle from aged miceGeorgia L Nolt, Alexander R Keeble, Yuan Wen, et al.
Nature Medicine|July 26, 2011
Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphomaTimothy Best, Dalin Li, Andrew D Skol, et al.
Breast Cancer Research and Treatment|April 4, 2014
Long-term risk of medical conditions associated with breast cancer treatmentDeirdre A Hill, Nora K Horick, Claudine Isaacs, et al.
JAMA|July 14, 2011
Clinically relevant changes in family history of cancer over timeArgyrios Ziogas, Nora K Horick, Anita Y Kinney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2006
Characterization of BRCA1 and BRCA2 mutations in a large United States sampleSining Chen, Edwin S Iversen, Tara Friebel, et al.
Pageof 34